Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Authors:
- Ali I. ShamseddineAli I. Shamseddine
- Fadi S. FarhatFFFadi S. Farhat
- 1 January 2011
- journal article
- review article
- Published by S. Karger AG in Chemotherapy
- Vol. 57 (6) , 468-487
Abstract
The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.Keywords
This publication has 148 references indexed in Scilit:
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experienceAnnals of Oncology, 2010
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialBreast Cancer Research and Treatment, 2009
- Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanesInvestigational New Drugs, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancerBreast Cancer Research and Treatment, 2008
- Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancerInvestigational New Drugs, 2007
- Phase II study of gemcitabine plus cisplatin in metastatic breast cancerAnti-Cancer Drugs, 2006
- Phase I study of spiroplatinEuropean Journal of Cancer and Clinical Oncology, 1991
- Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)European Journal of Cancer and Clinical Oncology, 1986